In a significant breakthrough, CRISPR gene editing has shown promising results in treating a rare form of blindness, according to a recent clinical trial. This development marks a significant milestone in the field of gene editing, demonstrating the potential of CRISPR to address various genetic disorders.
The clinical trial involved the use of CRISPR gene editing to treat a rare hereditary disorder called hereditary angioedema. The patients who received the in vivo CRISPR-based gene-editing therapy showed no serious side effects and nearly complete resolution of their symptoms. This success underscores the potential of CRISPR as a safe and effective gene-editing tool for treating genetic disorders.